{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:35:13Z","timestamp":1779244513821,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhltonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Heart and Lung Transplantation"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.healun.2013.08.010","type":"journal-article","created":{"date-parts":[[2013,9,10]],"date-time":"2013-09-10T09:44:51Z","timestamp":1378806291000},"page":"1114-1122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: Insights from the REVEAL Registry"],"prefix":"10.1016","volume":"32","author":[{"given":"Harrison W.","family":"Farber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dave P.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie A.","family":"Meltzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"McGoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.healun.2013.08.010_bib1","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.jacc.2009.01.004","volume":"53","author":"McLaughlin","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.healun.2013.08.010_bib2","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1378\/chest.06-2674","article-title":"Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines","volume":"131","author":"Badesch","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.healun.2013.08.010_bib3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jacc.2004.02.029","article-title":"Cellular and molecular pathobiology of pulmonary arterial hypertension","volume":"43","author":"Humbert","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.healun.2013.08.010_bib4","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","article-title":"Survival in patients with primary pulmonary hypertension. Results from a national prospective registry","volume":"115","author":"D\u2019Alonzo","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.healun.2013.08.010_bib5","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jacc.2005.04.050","article-title":"Ambrisentan therapy for pulmonary arterial hypertension","volume":"46","author":"Galie","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.healun.2013.08.010_bib6","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1164\/rccm.200307-957OC","article-title":"Sitaxsentan therapy for pulmonary arterial hypertension","volume":"169","author":"Barst","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.healun.2013.08.010_bib7","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.healun.2013.08.010_bib8","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","article-title":"Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study","volume":"358","author":"Channick","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.healun.2013.08.010_bib9","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group","volume":"334","author":"Barst","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2013.08.010_bib10","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/eurheartj\/ehp297","volume":"30","author":"Galie","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.healun.2013.08.010_bib11","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMra040291","article-title":"Treatment of pulmonary arterial hypertension","volume":"351","author":"Humbert","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2013.08.010_bib12","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/MAJ.0b013e31815d2647","article-title":"Pulmonary arterial hypertension","volume":"335","author":"Highland","year":"2008","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.healun.2013.08.010_bib13","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/01.CIR.0000029100.82385.58","article-title":"Survival in primary pulmonary hypertension: the impact of epoprostenol therapy","volume":"106","author":"McLaughlin","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.healun.2013.08.010_bib14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1742-1241.2010.02525.x","article-title":"How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension?","author":"Barst","year":"2010","journal-title":"Int J Clin Pract Suppl"},{"key":"10.1016\/j.healun.2013.08.010_bib15","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1161\/hc2901.093117","article-title":"Sildenafil inhibits hypoxia-induced pulmonary hypertension","volume":"104","author":"Zhao","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.healun.2013.08.010_bib16","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jacc.2003.10.056","article-title":"Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study","volume":"43","author":"Sastry","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.healun.2013.08.010_bib17","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2013.08.010_bib18","doi-asserted-by":"crossref","first-page":"485","DOI":"10.7326\/0003-4819-112-7-485","article-title":"Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial","volume":"112","author":"Rubin","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.healun.2013.08.010_bib19","first-page":"425","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease","volume":"132","author":"Badesch","year":"2000","journal-title":"A randomized, controlled trial. Ann Intern Med"},{"key":"10.1016\/j.healun.2013.08.010_bib20","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.healun.2007.01.035","article-title":"Management of pulmonary arterial hypertension with a focus on combination therapies","volume":"26","author":"Benza","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2013.08.010_bib21","doi-asserted-by":"crossref","first-page":"515","DOI":"10.7326\/0003-4819-136-7-200204020-00008","article-title":"Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension","volume":"136","author":"Ghofrani","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.healun.2013.08.010_bib22","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1183\/09031936.03.00008003","article-title":"Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids","volume":"22","author":"Hoeper","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1016\/j.healun.2013.08.010_bib23","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1183\/09031936.06.00057906","article-title":"Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension","volume":"28","author":"Hoeper","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.healun.2013.08.010_bib24","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1164\/rccm.200603-358OC","article-title":"Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension","volume":"174","author":"McLaughlin","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.healun.2013.08.010_bib25","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1097\/01.smj.0000217927.81107.65","article-title":"Long-term results after addition of sildenafil in idiopathic PAH patients on bosentan","volume":"99","author":"Minai","year":"2006","journal-title":"South Med J"},{"key":"10.1016\/j.healun.2013.08.010_bib26","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1378\/chest.07-2111","article-title":"Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan","volume":"134","author":"Benza","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.healun.2013.08.010_bib27","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0025-6196(11)60769-6","article-title":"Design of the REVEAL registry for US patients with pulmonary arterial hypertension","volume":"83","author":"McGoon","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.healun.2013.08.010_bib28","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1378\/chest.09-1140","article-title":"Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry","volume":"137","author":"Badesch","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.healun.2013.08.010_bib29","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/j.ehj.2004.09.014","article-title":"Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology","volume":"25","author":"Galie","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.healun.2013.08.010_bib30","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.jacc.2009.04.012","article-title":"Updated clinical classification of pulmonary hypertension","volume":"54","author":"Simonneau","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.healun.2013.08.010_bib31","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1378\/chest.10-0075","article-title":"The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries","volume":"139","author":"Frost","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.healun.2013.08.010_bib32","first-page":"1","article-title":"Deaths: final data for 2009","volume":"60","author":"Kochanek","year":"2012","journal-title":"Natl Vital Stat Rep"},{"key":"10.1016\/j.healun.2013.08.010_bib33","doi-asserted-by":"crossref","first-page":"35S","DOI":"10.1378\/chest.126.1_suppl.35S","article-title":"Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines","volume":"126","author":"Badesch","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.healun.2013.08.010_bib34","doi-asserted-by":"crossref","first-page":"409","DOI":"10.7326\/0003-4819-121-6-199409150-00003","article-title":"Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin","volume":"121","author":"Barst","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.healun.2013.08.010_bib35","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0735-1097(02)02012-0","article-title":"Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival","volume":"40","author":"Sitbon","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.healun.2013.08.010_bib36","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s12325-011-0005-5","article-title":"Prostacyclins in pulmonary arterial hypertension: the need for earlier therapy","volume":"28","author":"Vachiery","year":"2011","journal-title":"Adv Ther"},{"key":"10.1016\/j.healun.2013.08.010_bib37","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1183\/09031936.04.00051104","article-title":"Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension","volume":"24","author":"Hoeper","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.healun.2013.08.010_bib38","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1183\/09031936.04.00028404","article-title":"Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2","volume":"24","author":"Humbert","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.healun.2013.08.010_bib39","doi-asserted-by":"crossref","first-page":"521","DOI":"10.7326\/0003-4819-149-8-200810210-00004","article-title":"Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial","volume":"149","author":"Simonneau","year":"2008","journal-title":"Ann Intern Med"}],"container-title":["The Journal of Heart and Lung Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249813013922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249813013922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T15:12:16Z","timestamp":1762355536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053249813013922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S1053249813013922"],"URL":"https:\/\/doi.org\/10.1016\/j.healun.2013.08.010","relation":{},"ISSN":["1053-2498"],"issn-type":[{"value":"1053-2498","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: Insights from the REVEAL Registry","name":"articletitle","label":"Article Title"},{"value":"The Journal of Heart and Lung Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.healun.2013.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}